AGC has decided to invest over 100-billion to increase production capacity of its chlor-alkali business in Thailand through an expansion of two manufacturing sites, said Apic-online.
The company will boost the production capacity of AGC Vinythai Public Co. Ltd., a new company being established in July 2022 to integrate AGC's chlor-alkali business in the Indochina Peninsula (PCN, 22 Mar 2021, p 1).
Last year, AGC announced plans to integrate and reorganize its three consolidated subsidiaries and form a new company. The subsidiaries involved include Vinythai Public Co. Ltd. (VNT), AGC Chemicals (Thailand) Co. (ACTH) and AGC Chemicals Vietnam Co.
The expansion project will increase caustic soda capacity to 1.64-million t/y from 1.42-million t/y, vinyl chloride monomer capacity to 1.7-million t/y from 1.3-million t/y, and polyvinyl chloride capacity to 1.6-million t/y from 1.2-million t/y at the current VNT and ACTH sites. Operations are scheduled to start in the first quarter of 2025.
AGC has been studying this expansion and has obtained approval for the environmental impact assessment by the Thai environmental regulatory authority and has now decided to make the investment, AGC noted.
In addition, this capacity expansion will introduce the latest technologies that will improve energy efficiency and production efficiency to reduce environmental impact, the company added.
As per MRC, AGC has begun evaluating an expansion of production capacity at its chlor-alkali subsidiary, Vinythai, as part of its initiative to expand its chlor-alkali business in Thailand. The project would involve increasing the production capacity of polyvinyl chloride to 860,000 t/y from 300,000 t/y, vinyl chloride monomer to 830,000 t/y from 400,000 t/y and caustic soda to 590,000 t/y from 370,000 t/y. A final decision will be made based on the findings of the environmental and health impact assessments.
As MRC wrote before, in December 2016, CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins and AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announced that they had entered into a definitive agreement with CMC Biologics' shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC will acquire 100% of CMC Biologics' shares.
Asahi Glass Co., Ltd., more commonly known as AGC, is a global glass manufacturing company, headquartered in Tokyo. It is one of the core Mitsubishi companies.